Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06996236 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brimonidine Eye Drops in the Prevention of Myopia Progression

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 30, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.
Trial Details
NCT Number NCT06996236
Lead Sponsor Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Conditions
(from sponsor)		 Myopia
Related terms Myopia
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov